Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 43, showing 5 Applications out of 212 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s)

16.

ECCT/25/03/06   Sparkle Study-Site 1404
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Godfrey Allan Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
View

17.

ECCT/25/03/04   Ndovu RCT
    Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Bomu Hospital (Mombasa county)
 
View

18.

ECCT/25/03/03   ALIM STUDY
    Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial.   
Principal Investigator(s)
1. Dr. QUENTIN AWORI
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
View

19.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
View

20.

ECCT/25/01/01   FLORAL
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
2. Gertrude’s Children’s Hospital (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
View